Curative Ventures Research
Investment Thesis
Curative Ventures describes itself as a "capital and talent partner to category-defining biotech companies that are developing new therapies to dramatically improve patient outcomes." The firm is a Dallas, Texas-based biotech investment group, founded around 2010-2012 by Bronson Crouch, that backs therapeutics companies from formation through public exit, frequently taking an operationally hands-on role (Crouch himself has served as CEO/Chairman of one of the firm's portfolio companies, Instil Bio) rather than acting as a purely passive check-writer.
Stage Focus
The firm is not explicit about stage on its public site, but its investment history shows it engages very early - at company formation or seed/Series A - and follows on through later private rounds (e.g., Peloton Therapeutics' $150M Series E) before exit. This is consistent with a "company builder" model common among small biotech-focused investment groups rather than a single-stage specialist fund.
Check Size
No check size is disclosed on the website or in secondary sources. Given the firm's small, concentrated portfolio (five known companies over roughly a decade) and its role co-leading large rounds (e.g., the $125M Series B for TCR2 Therapeutics alongside Redmile Group), individual checks are likely substantial for a firm of its size, but a reliable range cannot be extracted with confidence.
Lead Tendency
Mixed/unclear. The firm has co-led at least one large round (TCR2 Therapeutics Series B, with Redmile Group) but its site does not consistently identify its role across the portfolio, so lead tendency is marked unknown.
Recent Activity
Curative Ventures' portfolio and press activity are concentrated in the 2012-2021 window, with one notable recent item: in August 2024, portfolio company Instil Bio announced a license and collaboration agreement with ImmuneOnco Biopharma for two bispecific antibody candidates (IMM2510 and IMM27M). Aside from that, there is no evidence of new portfolio company additions since 2020 (iTeos Therapeutics Series B-II, per third-party sources), suggesting the firm is not actively deploying new capital on a visible cadence and may be operating more as a steward of its existing, now largely public or acquired, portfolio.
Portfolio Highlights
Curative Ventures has backed five known biotech companies, with a strong track record of exits:
- Peloton Therapeutics - acquired by Merck in 2019 for up to $2.2B, bolstering Merck's oncology pipeline (HIF-2alpha inhibitor for renal cell carcinoma).
- CoStim Pharmaceuticals - a Cambridge, MA immuno-oncology company acquired by Novartis in February 2014 for up to $248M.
- TCR2 Therapeutics - T-cell receptor therapeutics company that IPO'd in February 2019; Curative co-led its $125M Series B with Redmile Group.
- iTeos Therapeutics - immuno-oncology company; Curative's most recent known investment was participation in its Series B-II in April 2020.
- Instil Bio - TIL (tumor-infiltrating lymphocyte) cell therapy company using its CoStAR platform; IPO'd in March 2021 (NASDAQ: TIL); Bronson Crouch serves as its CEO and Chairman, reflecting the firm's hands-on, talent-partner model.
Overall the portfolio has produced two IPOs (TCR2, Instil Bio) and two acquisitions (Peloton, CoStim) from just five known companies - an unusually high hit rate for a small, low-volume investor.
Team
- Bronson Crouch, Managing Partner / Founding Partner - Dallas-based biotech investor with a 15-year track record across Peloton Therapeutics, CoStim Pharmaceuticals, TCR2 Therapeutics, and iTeos Therapeutics. Also serves as CEO and Chairman of portfolio company Instil Bio, illustrating the firm's operator-investor model. No other team members are named on the public website; the firm appears to operate as a small, concentrated group rather than a traditional multi-partner fund.
Decision Process
Not disclosed; given the single named partner and small portfolio, likely a solo-GP or very small partnership structure, though this is inferred rather than confirmed.
Founder Preferences
No explicit founder-preference statement is published. The portfolio pattern (T-cell/immuno-oncology and cell-therapy platforms, several tracing back to MD Anderson/academic-adjacent science, Dallas/Texas ties for at least one company) suggests a preference for deeply technical, science-driven founding teams building novel therapeutic platforms rather than incremental biotech plays.
Geographic Focus
Headquartered in Dallas, TX (3963 Maple Avenue, Suite 350, Dallas, TX 75219), but its portfolio is geographically dispersed - CoStim was Cambridge, MA-based, while Instil Bio and other companies have ties to Dallas/Texas biotech. The firm does not appear to be geographically restrictive within the US.
Summary
Curative Ventures is a small, concentrated, Dallas-based biotech venture investor with an outsized track record (two IPOs, two acquisitions from five known portfolio companies) built around Managing Partner Bronson Crouch's operator-investor approach. Public information on current fund size, check size, and active deployment status is limited, and the firm's most recent visible activity (an August 2024 portfolio company licensing deal) is about a legacy holding rather than a new investment, suggesting the firm may not be in an active new-deployment phase.